S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
S&P 500   4,122.47 (-0.42%)
DOW   32,774.41 (-0.18%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NYSE:CRY

CryoLife - CRY Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$17.19
$21.72
52-Week Range
N/A
Volume
7,792 shs
Average Volume
198,221 shs
Market Capitalization
$703.22 million
P/E Ratio
596.20
Dividend Yield
N/A
Price Target
$25.00

CryoLife MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
∞ Upside
$25.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
600.00%
From $0.03 to $0.21 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

661st out of 1,098 stocks

Surgical & Medical Instruments Industry

68th out of 112 stocks

CRY stock logo

About CryoLife (NYSE:CRY) Stock

CryoLife, Inc. engages in the manufacture, process and distribution of medical devices and implantable human tissues. It operates through the Medical Devices and Preservation Services segments. The Medical Devices segment includes revenues from sales of BioGlue products, aortic stents and stent grafts, On-X products, CardioGenesis cardiac laser therapy, PerClot, and PhotoFix. The Preservation Services segment focuses on revenues from preservation of cardiac and vascular implantable human tissues. The company was founded on January 19, 1984 and is headquartered in Kennesaw, GA.

Receive CRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter.

CRY Stock News Headlines

See More Headlines

Receive CRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CryoLife and its competitors with MarketBeat's FREE daily newsletter.

CRY Company Calendar

Last Earnings
11/04/2021
Today
8/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
22890310
Employees
1,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$25.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$25.00
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-16,680,000.00
Pretax Margin
0.41%

Debt

Sales & Book Value

Annual Sales
$253.23 million
Book Value
$8.46 per share

Miscellaneous

Free Float
37,560,000
Market Cap
$703.22 million
Optionable
Optionable
Beta
1.53














CRY Stock - Frequently Asked Questions

Should I buy or sell CryoLife stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CryoLife in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRY, but not buy additional shares or sell existing shares.
View CRY analyst ratings
or view top-rated stocks.

What is CryoLife's stock price forecast for 2022?

1 Wall Street research analysts have issued 12-month price targets for CryoLife's stock. Their CRY share price forecasts range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next year.
View analysts price targets for CRY
or view top-rated stocks among Wall Street analysts.

How were CryoLife's earnings last quarter?

CryoLife, Inc. (NYSE:CRY) released its earnings results on Thursday, November, 4th. The medical equipment provider reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.22. The medical equipment provider earned $72.21 million during the quarter, compared to the consensus estimate of $72.90 million. CryoLife had a trailing twelve-month return on equity of 4.24% and a net margin of 0.63%. During the same quarter last year, the company posted $0.13 earnings per share.

What is J. Patrick Mackin's approval rating as CryoLife's CEO?

53 employees have rated CryoLife Chief Executive Officer J. Patrick Mackin on Glassdoor.com. J. Patrick Mackin has an approval rating of 81% among the company's employees.

What other stocks do shareholders of CryoLife own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CryoLife investors own include Energy Transfer (ET), AT&T (T), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Enterprise Products Partners (EPD), Gilead Sciences (GILD), Netflix (NFLX), Zoetis (ZTS), Ares Capital (ARCC) and Edwards Lifesciences (EW).

What is CryoLife's stock symbol?

CryoLife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

How much money does CryoLife make?

CryoLife (NYSE:CRY) has a market capitalization of $0.00 and generates $253.23 million in revenue each year. The medical equipment provider earns $-16,680,000.00 in net income (profit) each year or $0.03 on an earnings per share basis.

How many employees does CryoLife have?

CryoLife employs 1,200 workers across the globe.

How can I contact CryoLife?

CryoLife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The official website for the company is www.cryolife.com. The medical equipment provider can be reached via phone at (770) 419-3355, via email at investors@cryolife.com, or via fax at 770-426-0031.

This page (NYSE:CRY) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.